Fluocinolone acetonide (FA) intravitreal implant (Iluvien®) in the treatment of diabetic macular oedema (DMO) – Real world outcomes

Poster Details

First Author: C.Routledge UK

Co Author(s):    F. Mason   A. Bhatnagar                          

Abstract Details


We report outcomes of using FA implant in treating DMO in a clinical setting.


This study reports real world results from a single centre eye unit in the West Midlands, UK.


Retrospective notes review of DMO patients treated with FA (minimum 12-month follow-up). LogMAR visual acuity (VA), intraocular pressure (IOP) and optical coherence tomography (OCT) were recorded every visit.


26 Eyes of 24 patients were included. Baseline DMO duration ranged 12-103 months (mean 29). All eyes had ≥1 macular laser; 77% had previous anti-VEGF (range 3-10, mean 5). 16% had well-controlled IOP treated topically. Mean 12 month LogMAR VA improvement was 6.2 letters. 46% gained ≥5 letters, 27% gained ≥10, and 12% gained ≥15. 8% Lost ≥5, and 0% lost ≥10 letters. Central macular thickness (CMT) reduced from baseline 606μ±149μ to 419μ±143μ at 12 months. Following initial improvement in CMT, oedema recurred in 15% by month 9. 5 eyes (19%) had IOP >28mmHg. Control was achieved topically in 4 eyes; 1 eye needed SLT treatment.


After 12 months, our mean VA improvement was higher than in FAME (6.2 vs 2.5-5 letters). However, less patients improved ≥15 letters (12% vs 20-29%). This may be attributable to lesser mean disease chronicity, inclusion of co-morbidities, and worse initial disease severity in our clinical setting. In contrast to the 0% 6-18 month recurrence in FAME, oedema recurred in 15% of our patients despite a good initial response. Despite concerns regarding IOP, 0% required incisional glaucoma surgery, compared to 3.7% in FAME.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy